NEW YORK (GenomeWeb News) – Interleukin Genetics said today that it has signed an agreement allowing members of Amway Global to sell some of its genetic tests, and that Amway will help in marketing the tests through its organization.
The agreement covers Interleukin Genetics' Inherent Health testing line, including tests for weight management, heart health, nutrition, and bone health.
The Weight Management Genetic Test is used in a program to determine if an individual is likely to lose weight more from low-calorie or balanced diets, or from increased exercise based on genotype.
The Heart Health Genetic Test uses variations in the IL1 gene in order to determine predisposition for inflammation, which has been implicated as a risk factor for heart disease, the company said.
The Nutritional Needs Genetic Test uses variations in genes related to B-vitamin metabolism and potential cell damage due to oxidative stress, and the Bone Health Genetic Test, which is expected to be available by the end of 2009, identifies susceptibilities to spine fractures and low bone mineral density associated with osteoporosis.